Last reviewed · How we verify
YKP3089
At a glance
| Generic name | YKP3089 |
|---|---|
| Also known as | other anti-epileptic drug (AED), Cenobamate, cenobamate |
| Sponsor | SK Life Science, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures (PHASE1)
- Cenobamate Open-Label Extension Study for YKP3089C025 (PHASE3)
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures (PHASE3)
- A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures (PHASE2)
- Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions (PHASE1)
- Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet (PHASE1)
- Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures (PHASE3)
- Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YKP3089 CI brief — competitive landscape report
- YKP3089 updates RSS · CI watch RSS
- SK Life Science, Inc. portfolio CI